Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have been given an average rating of “Hold” by the eight ratings firms that are currently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.92.

Several research analysts have recently weighed in on the stock. Barclays cut their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Robert W. Baird cut their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th.

Certara Price Performance

Certara stock opened at $10.54 on Tuesday. Certara has a 12-month low of $9.41 and a 12-month high of $19.87. The stock has a market capitalization of $1.70 billion, a P/E ratio of -52.70, a P/E/G ratio of 5.86 and a beta of 1.53. The firm’s 50-day moving average is $10.75 and its two-hundred day moving average is $12.20. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company’s revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.06 EPS. Equities analysts predict that Certara will post 0.28 earnings per share for the current year.

Insider Buying and Selling at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.39% of the stock is owned by corporate insiders.

Institutional Trading of Certara

A number of hedge funds have recently made changes to their positions in the stock. Brown Brothers Harriman & Co. acquired a new position in Certara in the third quarter worth $27,292,000. Sei Investments Co. boosted its holdings in Certara by 39.5% in the second quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock worth $13,821,000 after purchasing an additional 282,357 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after purchasing an additional 1,128,006 shares during the period. Daventry Group LP boosted its holdings in Certara by 153.0% in the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after purchasing an additional 791,405 shares during the period. Finally, Kayne Anderson Rudnick Investment Management LLC boosted its holdings in Certara by 8.4% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 810,206 shares of the company’s stock worth $11,221,000 after purchasing an additional 62,912 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.